Literature DB >> 8497811

CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.

C J Hudson1, L T Young, P P Li, J J Warsh.   

Abstract

Until recently, research on the neurochemical basis of affective disorders (AD) and schizophrenia (SCZ) focused on detecting postulated disturbances in presynaptic neurotransmitter release and metabolism, or postsynaptic receptor function. New insights into the molecular mechanisms involved in the propagation of neurotransmitter signals across biological membranes and in the regulation of neuronal responses have allowed the development of novel hypotheses, which may explain the altered postsynaptic neuroreceptor responsivity thought to be integral to the pathophysiology of these disorders. In this review we evaluate evidence from both basic science and clinical research implicating disturbances in postreceptor signal transduction in the pathophysiology and pharmacotherapy of AD and SCZ. Specific findings regarding potential postreceptor sites of pathophysiology are highlighted in each of these disorders, together with the growing body of data on the possible postreceptor loci of psychotropic drug action, especially lithium and antidepressants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497811     DOI: 10.1002/syn.890130311

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

1.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.

Authors:  K V Chowdari; B Brandstaetter; P Semwal; T Bhatia; S Deshpande; R Reddy; J Wood; C R Weinberg; B K Thelma; V L Nimgaonkar
Journal:  Psychiatr Genet       Date:  2001-12       Impact factor: 2.458

Review 2.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 3.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

Review 5.  Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.

Authors:  António F Ambrósio; Patrício Soares-Da-Silva; Caetana M Carvalho; Arsélio P Carvalho
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

Review 6.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders.

Authors:  H K Manji; G Chen
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 8.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

9.  [3H]PtdIns hydrolysis in postmortem human brain membranes is mediated by the G-proteins Gq/11 and phospholipase C-beta.

Authors:  R S Jope; L Song; R Powers
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

10.  Heterotrimeric g proteins: insights into the neurobiology of mood disorders.

Authors:  Javier González-Maeso; J Javier Meana
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.